Royalty Report: Drugs, Cancer, Delivery – Collection: 274933

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Cancer
  • Delivery
  • Therapeutic
  • Pharmaceuticals
  • Disease
  • Respiratory

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 274933

License Grant
The Canadian Licensor hereby grants to Licensee and Licensee hereby accepts an exclusive sublicense under the Technology to make, have made, use, sell, offer for sale, sublicense, distribute, import, and have imported Product in the Licensee Field in the Territory.
License Property
US Patent Number 5,837,282 – Ionophore-Mediated Liposome Loading

Product means any one or more of Sphingosomal Vinorelbine and Sphingosomal Topotecan.

Sphingosomal Vinorelbine means a liposome that includes sphingomyelin and cholesterol and contains encapsulated vinorelbine, wherein the sphingomyelin comprises less than 20% dihydrosphingomyelin.

Sphingosomal Topotecan means a liposome that includes sphingomyelin and cholesterol and contains encapsulated topotecan, wherein the sphingomyelin comprises less than 20% dihydrosphingomyelin.

Field of Use
Marqibo (sphingosomal vincristine), INX-0125 (sphingosomal vinorelbine) and INX-0076 (sphingosomal topotecan) are proprietary drugs using INEX's proprietary sphingosomal drug delivery technology. This technology is designed to provide prolonged blood circulation, tumor accumulation and extended drug release at the cancer site. These characteristics are intended to increase the effectiveness while reducing the side effects of the encapsulated drug.
Marqibo has completed phase 2 clinical trials and is ready to enter phase 3 clinical trials in first-line aggressive non-Hodgkin's lymphoma and acute lymphoblastic leukemia. An Investigational New Drug (IND) application has been approved for the commencement of phase 1 clinical trials for INX-0125 in both the US and Canada and preclinical development is being completed for INX-0076.

IPSCIO Record ID: 286070

License Grant
With this agreement, the Parties are effecting the termination of the license by the Canadian Licensor to the Licensee of certain MD Anderson Patents, and the termination of all rights, responsibilities and obligations of Licensee associated therewith; and, affirming the continuation of the license by the Canadian Licensor to Licensee of the Licensed Patents for use in the Licensee Field, and affirming the continuation of all rights, responsibilities and obligations of Licensee associated therewith; and, effecting the license by Licensee to Licensor of the certain MD Anderson Patents for use outside the Licensee Field; all as contemplated the Transaction Agreement.

With this agreement, the Parties hereby agree
—  to terminate the exclusive license by Licensor to Licensee under the MD Anderson Patents,
—  to affirm Licensors grant to Licensee of an exclusive license under the Licensed Patents to make, have made, use, sell, offer for sale, import, and have imported Products in the Licensee Field within the Territory; and, an exclusive license to the Technology to make, have made, use, sell, offer for sale, import, and have imported Products in the Licensee Field within the Territory; and
—  to the irrevocable and absolute grant, sale,. assignment and conveyance by Licensor to Licensee, Licensors entire right, title end interest in and to the Thomas Patents set forth in the MD Anderson License; and, Licensors entire right, title and interest in and to Licensors joint ownership of the Sarris Patents subject to the terms and conditions set forth in the MD Anderson License.

License Property
Product means any one or more of Sphingosomal Vincristine, Sphingosomal Vinorelbine, and Sphingosomal Topotecan.

British Columbia Cancer Agency (BCCA) Patents means the egg sphingomyelin patents assigned by the BCCA to Licensor.

Marqibo is Licensee’s trade name for Sphingosomal Vincristine.

Sphingosomal Topotecan means a liposome that includes sphingomyelin and cholesterol and contains encapsulated topotecan, wherein the sphingomyelin comprises less than 20% dihydrosphingomyelin.

Sphingosomal Vincristine means a liposome that includes sphingomyelin and cholesterol and contains encapsulated vincristine, wherein the sphingomyelin comprises less than 20% dihydrosphingomyelin.

Sphingosomal Vinorelbine means a liposome that includes sphingomyelin and cholesterol and contains encapsulated vinorelbine, wherein the sphingomyelin comprises less than 20% dihydrosphingomyelin.

Field of Use
The Licensee Field means all uses of the Products.  The original transaction agreement included, but was not necessarily limited to, the pulmonary delivery of Ciprofloxacin.  Marqibo is used in adult patients with relapsed ALL, and  in patients with metastatic malignant uveal melanoma.

IPSCIO Record ID: 291110

License Grant
Canadian Licensor hereby grants to Licensee an exclusive license for the Field in the Territory under the Licensed Patents; and an exclusive license for the Field in the Territory under the Know-How; for the sole purpose of developing, making, having made, importing, using, offering for sale and selling Licensed Product in the Territory, including the right to grant sublicenses under these rights as set out in this Agreement.
License Property
Licensed Product means Ciprofloxacin encapsulated in the Licensor Liposome Technology and which is intended for pulmonary delivery.

Ciprofloxacin means the chemical compound known as ciprofloxacin, whose more specified chemical name is 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid and all pharmaceutically active salts thereof.

AERx Device means the durable hand-held device developed by Licensee for the delivery of Ciprofloxacin by inhalation and known as the AERx Device, as such device may be modified pursuant to the Agreement.

Loading Patents means the patents owned by University and exclusively licensed to Licensor and set out in Agreement.
5,800,833 – Method for loading lipid vesicles
5,785,987 – Method for loading lipid vesicles

Sphingosome Patents means the Patents owned by Licensor and set out in this Agreement.
5,543,152 – Sphingosomes for enhanced drug delivery

Licensed Patents means the Loading Patents and the Sphingosome Patents.

Patent means (a) all patent applications filed or having legal force in any country owned or controlled by Licensor as of the Effective Date; (b) all patents that have issued or in the future issue therefrom owned or controlled by Licensor as of the Effective Date, including without limitation utility, model and design patents and certificates of invention; and (c) all divisionals, continuations, continuations-in-part, reissues, renewals, extensions (including supplemental protection certificates), additions, registrations or confirmations to or of any such patent applications and patents.

Licensor Liposome Technology means Licensor’s proprietary liposomal drug delivery system that encapsulates drugs in sphingomyelin/cholesterol liposomes using a proton gradient generated by either an ionophore or methylammonium sulfate.

Field of Use
This agreement pertains to patented liposomal formulation technology for the pulmonary delivery of ciprofloxacin

Ciprofloxacin is a fluoroquinolone (flor-o-KWIN-o-lone) antibiotic that fights bacteria in the body. It is used to treat different types of bacterial infections, including skin infections, bone and joint infections, respiratory or sinus infections, urinary tract infections, and certain types of diarrhea.

IPSCIO Record ID: 3957

License Grant
The Licensor granted the Licensee an exclusive License under certain patents to commercialize the Optisome products for all uses throughout the world, and an exclusive License under certain patents held by the Licensor to commercialize the Optisome products for all uses throughout the world under the terms of certain research Agreements between the Licensor and the British Columbia Cancer Agency, and an exclusive License to all technical information and know-how relating to the technology claimed in the patents held exclusively by the Licensor and to all confidential information relating to the Optisome products to commercialize the Optisome products for all uses throughout the world.
License Property
Optisomes are a new generation of unique, sphingomyelin/cholesterol-based nanoparticles designed to encapsulate cell cycle-specific chemotherapeutic to improve efficacy and reduce toxicity. Optisomes are approximately 100 nanometers in diameter and able to encapsulate and transport cancer drugs preferentially to tumor sites. While too large to easily migrate out of normal blood vessels, Optisomes are able to migrate across the more leaky vasculature of a tumor, resulting in higher concentrations of drugs at tumor sites than in normal tissue. Optisomes' unique sphingomyelin-cholesterol composition is particularly well suited to cell cycle-specific agents such as vincristine, vinorelbine and topotecan. The relative rigidity of the Optisomes' outer shell results in a long circulating half-life and sustained drug release at the tumor site, which may increase tumor cell exposure during the most vulnerable phases of cell division. Combined, these factors are key to the Optisome advantage as sustained drug exposure increases tumor cell death.
Field of Use
The Licensee has the right to grant subLicenses to third parties and in such event the parties will share sublicensing revenue received by us at varying rates for each Optisome product depending on such Optisome product’s stage of clinical development.  Under the License Agreement, we also granted back to the Licensor a limited, royalty-free, non-exclusive License in certain patents and technology owned or Licensed to us solely for use in developing and commercializing liposomes having an active agent encapsulated, intercalated or entrapped therein.  Licensee's Optisome pipeline includes Marqibo(r) (vincristine), Alocrest(tm) (vinorelbine) and Brakiva(tm) (topotecan).

IPSCIO Record ID: 25841

License Grant
We completed a transaction with the Licensor pursuant to which we acquired exclusive, worldwide rights to develop and commercialize three product candidates Marqibo, sphingosome encapsulated vinorelbine and sphingosome encapsulated topotecan, collectively called the Licensed Products.
Field of Use
The Licensor is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care. We seek to license novel, late       preclinical and early clinical oncology product candidates, primarily from academia and research institutes, in order to accelerate clinical development and time to commercialization.

IPSCIO Record ID: 6987

License Grant
The Licensee completed a transaction with the Licensor, to acquire exclusive, worldwide rights to develop and commercialize Marqibo, Alocrest and Brakiva, collectively refered to as the Optisome products.

This exclusive License is under certain patents held by the Licensor to commercialize the Optisome products for all uses throughout the world under the terms of certain research Agreements between the Licensor and the British Columbia Cancer Agency.

License Property
Under the License Agreement, Licensor will be the owner of patents and patent applications claiming priority to certain patents Licensed to us, and we have an obligation to assign to Licensor our rights to inventions covered by such patents or patent applications.

Marqibo® (vincristine sulfate liposomes injection) is a novel, targeted Optisome™ encapsulated formulation product candidate of the Food and Drug Administration (FDA)-approved anticancer drug vincristine, currently in development primarily for the treatment of adult acute lymphoblastic leukemia, or ALL, in second relapse or that has progressed following two or more prior lines of anti-leukemia therapy.

Brakivaâ„¢ (topotecan liposome injection), a novel targeted Optisomeâ„¢ encapsulated formulation product candidate of the FDA-approved anticancer drug topotecan.

Alocrestâ„¢ (vinorelbine liposome injection), a novel, targeted Optisomeâ„¢ encapsulated formulation product candidate of the FDA-approved anticancer drug vinorelbine.

Field of Use
The Licensee has the right to grant subLicenses to third parties and in such event Licensee and Licensor will share sublicensing revenue.

Under the License Agreement, Licensee also granted back to Licensor a limited, royalty-free, non-exclusive License in certain patents and technology owned or Licensed to us solely for use in developing and commercializing liposomes having an active agent encapsulated, intercalated or entrapped therein.

IPSCIO Record ID: 27226

License Grant
We signed a licensee agreement to develop and commercialize liposome encapsulated doxorubicin (LED), liposome compounds worldwide.

LED allows cancer Phase I Breast, Prostate, 2 Patents patients to tolerate higher completed, Hematological dosages of chemotherapy initiated providing greater therapeutic Phase II in value in a number of types of June 1998 cancer tumors; liposome products consist of spheres of sub cellular size composed primarily of phospholipids, certain of which are the primary components of living cell membranes, and can be made to contain and deliver drugs.  This membrane encapsulation feature of liposome enables the entrapped drug to be circulated in the bloodstream in higher concentrations for longer periods of time than the free drug – clinical trial.  Pursuant to the license agreement, the Licensee agreed to assume all further responsibility for, and the costs associated with, the further development and testing of LED and LEP and the obtaining of all regulatory approvals.

IPSCIO Record ID: 27197

License Grant
We signed a license agreement to develop and commercialize liposome encapsulated paclitaxel (LEP).
License Property
LEP allows cancer patients to tolerate higher dosages of chemotherapy, providing greater therapeutic value in a number of types of cancer tumors; liposome compounds worldwide; liposome products consist of spheres of sub cellular size composed primarily of phospholipids, certain of which are the primary components of living cell membranes, and can be made to contain and deliver drugs.  This membrane encapsulation feature of liposomes enables the entrapped drug to be circulated in the bloodstream in higher concentrations for longer periods of time than the free drug.  We initiated a Phase I clinical study on LEP in September of 1998 for patients with lung cancer.
Field of Use
The rights granted apply to cancer.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.